Evidence map›Paper›PMID 42645403›Full record

ArticleArchives of toxicology2026

Pregnane X receptor-mediated liver growth: a controlled clinical trial in healthy volunteers and identification of the role of AKT-MTOR pathway in mouse.

Piia Lassila, Mikko Karpale, Outi Kummu, Aaron Stahl, Aki Käräjämäki, Eija Pääkkö, Helen Sophie Hammer, Albert Braeuning, Oliver Pötz, Markus Templin and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Piia LassilaResearch Unit of Biomedicine and Internal Medicine, Pharmacology and Toxicology, Biocenter Oulu, Medical Research Center Oulu, Oulu University Hospital, University of Oulu, POB 5000, 90014, Oulu, Finland.
Mikko KarpaleResearch Unit of Biomedicine and Internal Medicine, Pharmacology and Toxicology, Biocenter Oulu, Medical Research Center Oulu, Oulu University Hospital, University of Oulu, POB 5000, 90014, Oulu, Finland.
Outi KummuResearch Unit of Biomedicine and Internal Medicine, Pharmacology and Toxicology, Biocenter Oulu, Medical Research Center Oulu, Oulu University Hospital, University of Oulu, POB 5000, 90014, Oulu, Finland.
Aaron StahlNMI Natural and Medical Sciences Institute at the University Tübingen, Reutlingen, Germany.
Aki KäräjämäkiResearch Unit of Biomedicine and Internal Medicine, Pharmacology and Toxicology, Biocenter Oulu, Medical Research Center Oulu, Oulu University Hospital, University of Oulu, POB 5000, 90014, Oulu, Finland.
Eija PääkköDepartment of Diagnostic Radiology, Oulu University Hospital, Oulu, Finland.
Helen Sophie HammerSIGNATOPE GmbH, Reutlingen, Germany.
Albert BraeuningDepartment of Food Safety, German Federal Institute for Risk Assessment (BfR), Berlin, Germany.
Oliver PötzNMI Natural and Medical Sciences Institute at the University Tübingen, Reutlingen, Germany.
Markus TemplinNMI Natural and Medical Sciences Institute at the University Tübingen, Reutlingen, Germany.
Janne HukkanenResearch Unit of Biomedicine and Internal Medicine, Pharmacology and Toxicology, Biocenter Oulu, Medical Research Center Oulu, Oulu University Hospital, University of Oulu, POB 5000, 90014, Oulu, Finland.
Jukka HakkolaResearch Unit of Biomedicine and Internal Medicine, Pharmacology and Toxicology, Biocenter Oulu, Medical Research Center Oulu, Oulu University Hospital, University of Oulu, POB 5000, 90014, Oulu, Finland. jukka.hakkola@oulu.fi.ORCID https://orcid.org/0000-0001-5048-4363

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pregnane X receptor (PXR) is a nuclear receptor acting as a master xenobiotic receptor for many exogenous chemicals. Activation of PXR has been linked to liver growth in mice, usually via interaction with Yes-associated protein (YAP), but this adaptive response has not been observed in humans. We investigated the effect of human PXR agonist, rifampicin, on liver size in a controlled clinical trial in healthy volunteers. Moreover, we developed a novel protocol to reveal mechanisms of PXR-mediated liver growth in mice. One-week rifampicin treatment caused a 2.7% mean increase in liver volume-to-body weight ratio without affecting liver fat content in human volunteers (n=16). Pxr

Indexed as

AKTLiver hypertrophyMTORPCNPXRRifampicin

Identifiers

PMID42645403

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.